Ascentage Pharma to Present Six Clinical Study Abstracts, Including Three Rapid Oral Presentations, at ASCO 2026

summarizeSummary

Ascentage Pharma will present data from six clinical studies, including three rapid oral presentations, at the 2026 ASCO Annual Meeting, showcasing progress for its key oncology drug candidates.

check_boxKey Events

• Six Abstracts Accepted for ASCO 2026

  Ascentage Pharma will present data from six clinical studies at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, held from May 29 to June 2, 2026.

• Three Rapid Oral Presentations

  Three of the six accepted abstracts have been selected for rapid oral presentations, indicating significant interest in the data for Olverembatinib, Lisaftoclax, and Alrizomadlin.

• Focus on Key Drug Candidates

  The presentations will feature data from three of the company's key drug candidates: Olverembatinib (third-generation BCR-ABL inhibitor), Lisaftoclax (Bcl-2 selective inhibitor), and Alrizomadlin (MDM2-p53 inhibitor).

auto_awesomeAnalysis

This announcement highlights Ascentage Pharma's significant progress in its clinical pipeline, with six abstracts accepted for presentation at the prestigious ASCO 2026 Annual Meeting. The inclusion of three rapid oral presentations for key drug candidates (Olverembatinib, Lisaftoclax, and Alrizomadlin) underscores the perceived importance and potential clinical value of the company's research by the global scientific community. This high visibility at a premier oncology conference can enhance investor confidence and attract further attention to the company's innovative therapies.